Maralixibat FDA Approval Status
FDA Approved: No
Generic name: maralixibat
Company: Mirum Pharmaceuticals, Inc.
Treatment for: Cholestatic Pruritus in Patients with Alagille Syndrome
Maralixibat is an inhibitor of the apical sodium dependent bile acid transporter (ASBT) in development for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS).
Development Timeline for maralixibat
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.